We are thrilled to share that Opticyte is a finalist for the MedTech Innovator & AdvaMed Execution Award! This award recognizes strong leadership teams with next-generation innovations and the resources to successfully execute their goals of improving patient care.

Opticyte was selected as one of the 5 finalists out of the 61 companies in the 2023 accelerator cohort. It is an honor to be recognized among top #MedTech companies for our novel technology and vision to bring it to market.

You can read the full press release here.